Abstract：Objective To investigate the relationship between hyperhomocysteinemia (HHcy) and intravenous thrombolytic therapy of urokinase in patients with acute cerebral infarction. Methods From Apirl 2012 to May 2015, in Yunfu City People's Hospital, 91 patients with acute cerebral infarction were selected, the plasma homocysteine (Hcy) concentration was measured and they were divided into HHcy group (48 cases) and non-HHcy group (43 cases). All patients were treated with intravenous thrombolytic therapy of urokinase, the treatment time was 2 weeks, the neurological deficits, clinical treatment effect, daily living ability, vascular recanalization and incidence of adverse reactions were observed. Results The NIHSS scores of the two groups before treatment were not statistically significant (P > 0.05). The NIHSS scores of the two groups at 12 h, 48 h and 7 d were significantly lower than those before treatment (P < 0.05), these of non-HHcy group were lower than those of HHcy group at the same time (P < 0.05),these of the two groups at 48 h were lower than those at 12 h (P < 0.05), these of the two groups at 7 d were lower than those at 48 h (P < 0.05). The effective rate of non-HHcy group was significantly lower than that of HHcy group (P < 0.05), and the total effective rate of non-HHcy group was significantly lower than that of HHcy group (P < 0.05). The life self-care rate of non-HHcy group was significantly higher than that of HHcy group (P < 0.05). The recanalization rate of non-HHcy group was significantly higher than that of HHcy group (P < 0.05). The incidence of adverse reactions in HHcy group was significantly higher than that in non-HHcy group (P < 0.05). Conclusion The using of urokinase intravenous thrombolysis in the treatment of acute cerebral infarction, non-HHcy patients can significantly improve neurological deficits, improve daily living ability and clinical treatment.
2017, Vol. 14 
京公网安备 11010502046598号